MSD Submits Marketing Application in EU for Oral PCSK9i Enlicitide

MSD has announced in its Q1 2026 report that it has submitted a marketing authorisation application to the European Medicines Agency (EMA) for its oral PCSK9 inhibitor, enlicitide, for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia. Enlicitide is an oral cyclic peptide designed to inhibit PCSK9, a protein that increases levels of low-density lipoprotein cholesterol (LDL-C) in the blood. The submission aims to provide a convenient, non-injectable alternative to existing PCSK9-targeting therapies.

The application is supported by positive data from three Phase III trials. The CORALreef Lipids study demonstrated a 57.1% reduction in LDL-C levels compared to a 3.0% increase for placebo. The CORALreef AddOn study showed enlicitide was superior to other oral non-statin treatments, and the CORALreef HeFH study confirmed efficacy in patients with heterozygous familial hypercholesterolaemia. The drug was well-tolerated across the program, with a safety profile comparable to placebo.

According to PharmCube's NextBiopharm® database, MSD could place the first PCSK9 inhibitor on the market ahead of 16 other active projects. Click here to request a free trial for NextBiopharm®.

Daily News
Novo Launches Insulin/GLP-1 Combo Icosema Globally First in China
2026-06-15
Thederma's Benvitimod Breaks New Ground in Infant Atopic Dermatitis
2026-06-15
Novartis Expands Molecular Glue Collaboration with Orionis
2026-06-12
WestGene, Cartesian Partner on In Vivo CAR-T, TCE Therapies
2026-06-12
Laekna Out‑Licenses PI3Kα Inhibitor in Deal Worth up to USD 517mn
2026-06-11
Latest Report
TOP-25 Drug Targets
Details